Kristina Jenei, Registered Nurse of Oncology at The Royal Marsden NHS Foundation Trust, shared a post on LinkedIn:
“Our new Correspondence in The Lancet: Cancer medicines remain absent from global access metrics, co-authored with Richard Sullivan
Late last year, the World Health Organization quietly updated their ‘access to medicines indicator’ (SDG 3.b.3) to encompass a wider set of tracer indications. However, despite the update, cancer medicines were not included despite being a leading cause of premature mortality worldwide.
This represents a bigger problem: Global monitoring frameworks continue to prioritise infectious diseases and reproductive health, leaving oncology largely invisible.
Without basic service and access indicators, bottlenecks cannot be diagnosed and progress cannot be measured. If cancer is to be treated as a genuine global health priority, measurement needs to catch up with disease burden.
Grateful to The Lancet Group for publishing.”
Title: Cancer medicines remain absent from global access metrics
Authors: Kristina Jenei, Richard Sullivan
Read the Full Article on The Lancet
More posts featuring Kristina Jenei.